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1. Introduction 
Fibrin-stabilizing factor (FSF; factor XIII) is a cal- 
cium-dependent enzyme, probably present in plasma 
as an inactive precursor; on activation it is responsible 
for the conversion of soluble to insoluble fibrin dur- 
ing the terminal stage of blood coagulation. 
While investigating factors affecting the rate of fi- 
brin stabilization it was observed that this occurred more 
rapidly if the plasma nd fibrinogen solution were in 
contact prior to clotting by a calcium-thrombin solu- 
tion. This was further investigated as follows. 
2. Methods and results 
Pooled citrated plasma in equal quantities from 10 
normal subjects diluted to twice its volume with tris 
buffer (pH 7.4; ionic strength 0.15) was used as a 
source of FSF. Human fibrinogen (Lister Institute) was 
made up to a concentration of 1.0 mg/ml in tris buf- 
fer (pH 7.4; ionic strength 0.15) and the solution shown 
to be free of FSF activity before use by clotting 1.0 ml 
(25 units) of  a fresh solution of thrombin (S.Maw, Son 
and Sons Ltd.) in 1% calcium chloride, allowing 30 min 
for stabilization, and demonstrating immediate solubil- 
ity of this clot in 2.0 ml of 2% monochloroacetic a id. 
The following mixture was prepared (ml): 
Pooled normal plasma 0.3 
Saline (0.9%) 0.2 
Fibrinogen (1.0 mg/ml) 1.0 
and was clotted by 1 ml of a fresh solution of calcium- 
thrombin (25 units/ml in 1% calcium chloride) imme- 
diately after the fibrinogen solution had been added 
to the plasma nd saline. An identical mixture was 
preincubated for 2 hr, and on another occasion for 3 
hr, and then clotted by the addition of 1.0 ml calcium- 
thrombin. The rate of conversion of soluble to insol- 
uble fibrin was measured as previously described [ 1 ]. 
Controls using saline instead of plasma showed no in- 
soluble fibrin formed. All assays were performed in 
duplicate. 
The results are shown in table 1. It can be seen that 
fibrin stabilization is more rapid if fibrinogen solution 
is incubated with plasma prior to clotting. 
A posssible xplanation of this phenomenon is that 
for optimal FSF activity, fibrinogen and FSF need 
time to react together in some way prior to clotting. 
This possibility was investigated as follows. 
The rate of insoluble clot formation was determined 
using the following clotting mixtures (ml): 
(a) Pooled normal plasma 0.3 
Saline (0.9%) 0.3 
Fibrinogen (1.0 mg/ml) 1.0 
(b) Pooled normal plasma 0.3 
Plasma from a patient with 
congenital deficiency of FSF 0.3 
Fibrinogen (1.0) mg/ml) 1.0 
In (b) the FSF-free plasma nd fibrinogen were 
mixed 3 hr before their addition to the pooled normal 
plasma. 
1.0 ml of calcium-thrombin was added to both (a) 
and (b) immediately after the addition of the fibrinogen 
or fibrinogen-FSF-free plasma mixture to the pooled 
normal plasma. Thus the fibrinogen was not allowed 
to incubate with normal plasma prior to clotting but 
in (b) it had incubated with FSF-free plasma prior to 
clotting. 
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Table 1 
Effect on the rate of fibrir, stabilization ofprior incubation of 
fibrinogen with normal plasma prior to clotting. 
Source of Incubation time Rate of fibrin 
fibrinogen of fibrinogen stabilization 
with plasma (hr) (mg/min) 
Lister Institute 2 0.264 
(human) negligible 0.125 
Lister Institute 3 0.306 
(human) negligibl~' 0.100 
Kabi, Grade L lr 0.577 
(human, lyogttilized) negligible 0.170 
Kabi, Grade B,I 1 0.134 
(bovine, lgophilized) negligible zero 
The rote of fibrin stabilization of (a) was 0.105 
mg/min and of (b) was 0.817 mg/min. 
Thus incubation of fibrinogen with FSF-free plas- 
ma prior to clotting resulted in more rapid fibrin sta- 
bilization and this rules out the suggested explanation 
of an association between FSF and fibrinogen. Mix- 
ture (b) contains lightly more fibrinogen than mix- 
ture (a) due to that present in the FSF-free plasma. 
This would produce slightly more rapid stabilization 
of fibrin but would certainly not account for the dif- 
ference since addition of this amount of fibrinogen 
(0.1 mg) would cause an increase of only about 0.03 
mg/min [1 ]. 
A further possible xplanation is that the low-tem- 
perature, ether-fraction technique, used to prepare the 
purified fibrinogen might have caused a biochemical 
or biophysical change modifying the ability of the fi- 
brinogen to form stabilized fibrin, and that this could 
be reversed by re-exposure to plasma. Thus fibrinogen 
(Kabi) prepared by ethanol fractionation i the presence 
of glycine at -3% [2] was subjected to the same test. 
Solutions (1.0 mg/ml) of fibrinogen (Kabi) grade 
L (human, lyophilized) and grade B1 (bovine, lyophil- 
ized) in tris buffer (pH 7.4; ionic strength 0.15) were 
incubated in a water bath at 40 ° for 3 hr to destroy 
any contaminating FSF. The absence of FSF was con- 
firmed as described above. Each FSF-free fibrinogen 
preparation was then assayed as described above to de- 
termine the effect of prior incubation with normal plas- 
ma on the rate of fibrin stabilization. 
The results are shown in table 1. The two prepara- 
tions of fibrinogen Kabi showed the same phenom- 
enon as the fibrinogen supplied by the Lister Institute 
in that stabilization of fibrin is more rapid after prior 
incubation of fibrinogen with normal plasma. The mag- 
nitude of the effect of preincubation appears different 
for the different sources of fibrinogen. This might well 
reflect changes in the fibrinogen produced by the meth- 
od of preparation since the rate of stabilization without 
preincubation is different for the different ypes of fibrin. 
ogen. 
3. Conchfions 
These results uggest the existence of a hitherto 
undescribed plasma factor which modifies in such a 
way as to prepare it for subsequent rapid stabilization 
when it is converted to fibrin. This occurred with two 
different preparations of human fibrinogen and also 
with one preparation of bovine fibrinogen and it there- 
fore seems unlikely that this property is induced dur- 
ing the process of preparation, but even if this proves 
to be the case the existence of a hitherto unknown 
plasma factor acting on the fibrinogen must still be in- 
ferred. 
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